SAN DIEGO--(BUSINESS WIRE)--Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through mRNA delivery using targeted lipid nanoparticles (tLNP), today announced the appointment of Ramin Farzaneh-Far, M.D., as Chief Medical Officer and the promotion of Miguel Arcinas to Senior Vice President, Corporate Development..

圣地亚哥--（商业新闻短讯）--Capstan Therapeutics，Inc.（“Capstan”），一家致力于通过使用靶向脂质纳米颗粒（tLNP）的mRNA递送促进细胞体内重编程的生物技术公司，今天宣布任命医学博士Ramin Farzaneh Far为首席医疗官，并将Miguel Arcinas晋升为企业发展高级副总裁。。

Dr. Farzaneh-Far brings to Capstan over 15 years of experience in the design, implementation, and interpretation of clinical trials across all phases of development and multiple therapeutic areas, including autoimmune disease.

Farzaneh Far博士在设计，实施和解释临床试验的各个发展阶段和多个治疗领域（包括自身免疫性疾病）方面拥有超过15年的经验。

“As we prepare to advance our in vivo technology to the clinic, Ramin’s track record in autoimmune disease drug development, his passion for advancing novel therapies for patients, and his leadership experience at multiple successful biotechnology companies will be invaluable to our organization,” said Dr.

“随着我们准备将体内技术推向临床，拉明在自身免疫性疾病药物开发方面的记录，他对推进患者新疗法的热情，以及他在多家成功的生物技术公司的领导经验，对我们的组织将是无价的，”博士说。

Laura Shawver, President and Chief Executive Officer of Capstan. “We are thrilled to have Ramin join our executive leadership team and to share in our vision of multiplying the therapeutic possibilities for patients.”.

LauraShawver，Capstan总裁兼首席执行官。“我们很高兴Ramin加入我们的执行领导团队，并分享我们对增加患者治疗可能性的愿景。”。

Dr. Farzaneh-Far joins Capstan from RA Capital where he has been a Venture Partner since 2020. Previously, he was Chief Medical Officer at Ra Pharmaceuticals from 2016 until its acquisition by UCB in 2020 and led the clinical development of zilucoplan (Zilbrysq ®), a complement C5 inhibitor recently approved in the United States, Europe, and Japan for the treatment of generalized myasthenia gravis.

Farzaneh Far博士从RA Capital加入Capstan，自2020年以来一直是该公司的风险合伙人。此前，他从2016年起担任Ra制药公司的首席医疗官，直到2020年被UCB收购，并领导了zilucoplan（Zilbrysq®）的临床开发，zilucoplan是一种补体C5抑制剂，最近在美国，欧洲和日本被批准用于治疗全身性重症肌无力。

He previously led global clinical development programs at Akebia Therapeutics and Gilead Sciences. Dr. Farzaneh-Far completed his internal medicine residency at Brigham and Women’s Hospital in Boston and a fellowship in cardiovascular medicine at the University of California, San Francisco (UCSF). He holds B.A.

他曾领导阿克比亚治疗学和吉利德科学公司的全球临床开发项目。Farzaneh Far博士在波士顿的Brigham and Women's Hospital完成了内科住院医师的实习，并在加州大学旧金山分校（UCSF）获得了心血管医学奖学金。他拥有学士学位。

and M.A. degrees in immunology from the University of Cambridge, an M.D. from University College London, and an MAS in clinical research from UCSF..

剑桥大学免疫学硕士学位，伦敦大学学院医学博士学位，加州大学旧金山分校临床研究硕士学位。。

“Capstan is ideally positioned to be the leader in in vivo CAR-T therapy, and has the potential to positively impact the lives of millions of patients who suffer from B cell mediated autoimmune disorders,” said Dr. Farzaneh-Far. “I look forward to working with Capstan’s accomplished and experienced leadership team to advance potentially transformative therapies to the clinic.”.

Farzaneh Far博士说：“绞盘是体内CAR-T治疗的领导者，有可能对数百万患有B细胞介导的自身免疫性疾病的患者的生活产生积极影响。”。“我期待着与Capstan有成就和经验的领导团队合作，将潜在的变革性疗法推向临床。”。

Mr. Arcinas brings extensive leadership experience in biopharma corporate development, strategy, and will continue to lead corporate development initiatives for Capstan. “Miguel’s broad-based experience in strategic partnerships and transactions, capital formation, and platform expansion will be critical in helping drive the next phase of growth for Capstan,” said Dr.

Arcinas先生在生物制药企业发展和战略方面拥有丰富的领导经验，并将继续领导Capstan的企业发展计划。“米格尔在战略合作伙伴关系和交易、资本形成和平台扩展方面的广泛经验，对于帮助推动Capstan下一阶段的增长至关重要，”Dr。

Shawver. “I am pleased to announce Miguel’s promotion in recognition of his contributions to the organization.”.

肖弗。“我很高兴宣布米格尔升职，以表彰他对组织的贡献。”。

Mr. Arcinas joined Capstan in 2021 as the company’s Vice President of Corporate Development. He has over 15 years of multi-disciplinary experience in biotech corporate strategy, business development, investor relations, and clinical operations. Prior to Capstan, Mr. Arcinas served as Vice President of Corporate Development and Investor Relations at Silverback Therapeutics, contributing to the company’s Series C financing, IPO, and merger activities.

Arcinas先生于2021年加入Capstan，担任公司企业发展副总裁。他在生物技术公司战略、业务发展、投资者关系和临床运营方面拥有超过15年的多学科经验。在加入Capstan之前，Arcinas先生曾担任Silverback Therapeutics公司的公司发展和投资者关系副总裁，为公司的C系列融资、IPO和合并活动做出了贡献。

He has held corporate development and operational roles of increasing responsibility at biopharma companies including Synthorx (acquired by Sanofi), Acadia Pharma, and Ignyta (acquired by Roche). Mr. Arcinas holds an MBA from the University of Chicago Booth School of Business and a B.S. from the University of California, Los Angeles..

他在生物制药公司（包括Synthorx（被赛诺菲收购）、Acadia Pharma和Ignyta（被罗氏收购））担任企业发展和运营角色，承担着越来越大的责任。Arcinas先生拥有芝加哥大学布斯商学院的MBA学位和加利福尼亚大学洛杉矶分校的学士学位。。

About Capstan Therapeutic, Inc. (www.capstantx.com)

关于Capstan Therapeutical，Inc.（www.capstantx.com）

Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The core platform technology comprises proprietary targeted lipid nanoparticles (tLNPs) that are composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody.

Capstan是一家生物技术公司，其使命是通过开发靶向体内RNA技术来增加患者的治疗可能性。核心平台技术包括专有的靶向脂质纳米颗粒（TLNP），其由与重组蛋白质粘合剂（例如单克隆抗体）缀合的LNP组成。

tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. The platform technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders.

tLNPs旨在提供有效载荷，包括mRNA或基因编辑工具，能够在体内重新编程特定的细胞类型。该平台技术有可能产生转化疗法，并可能应用于广泛的疾病领域，包括自身免疫性疾病，肿瘤学，纤维化和单基因血液疾病。

For more information, please visit www.capstantx.com and follow us on LinkedIn..

有关更多信息，请访问www.capstantx.com并在LinkedIn上关注我们。。